FibroFind have established 3D human tissue models of fibrosis in multiple organs that maintain the architectural integrity, functionality and metabolic activities of the tissue over an extended period (6 days+). All major epithelial, endothelial and resident immune cell types are maintained and the tissue responds dynamically to physiologically relevant inducers of fibrosis. These platforms validate drug targets and efficacy of candidate drugs through a variety of readouts include soluble matrix factors, gene expression and histology.
SCREEN is a leader in the areas of imaging and electronics technology. Scientists at SCREEN have implemented their technology in the Life Sciences by developing robust,
versatile imaging platforms with a broad spectrum of applications for 2D and 3D in vitro and ex vivo assays to perform high-speed imaging and analysis of the phenotypic and morphological changes in complex 3D cellular/tissue structures. Additionally, SCREEN’s MED64 electrophysiology platforms provide the most-sensitive microelectrode arrays for
label-free functional assays with stem cell-derived cardiomyocytes or/and neurons. SCREEN technology is accelerating research in the field of regenerative medicine, multiple disease areas including oncology/immune-oncology and neurodegenerative diseases.
Newcells Biotech is a fast-growing team of global scientific and industry experts based in state-of-the-art facilities in the Helix Science Campus of Newcastle-upon-Tyne in the UK.
Our purpose is to bridge the gap between scientific discovery and patients and we make a difference by providing better predictions of clinical outcomes. Using our expertise in
induced pluripotent stem cells (iPSCs), cellular physiology, and organoid technology, we build functional preclinical in vitro models of retina, kidney, liver, and lung.
Corning is a global, leading manufacturer of lab tools for growing cells, bioprocess manufacturing, liquid handling, benchtop equipment, among other solutions for life sciences. Corning strives to improve efficiencies and develop innovations that enable researchers to create breakthrough discoveries in areas like cancer, primary cells, stem cells, drug discovery, cell and gene therapy and lab automation. Learn more about Corning's novel 3D cell culture tools for oncology assays and high throughput screening by visiting:
Vyant Bio, a NASDAQ-listed biotechnology company, is reinventing drug discovery for complex neurodevelopmental and neurodegenerative brain disorders. Our CNS drug discovery platform combines human patient-derived organoid models of brain disease, scaled biology and machine learning to elucidate disease pathophysiology; to formulate key therapeutic hypotheses; to identify and validate drug targets, cellular assays and biomarkers to guide candidate molecule selection; and to guide patient selection and clinical trial design.
Alcyomics® is a leading CRO for the development of skin explant and 3D culture assays for the detection of adverse immune events and pre-clinical drug discovery and screening. Skimune® and Skimune 3D® are powerful tools for the prediction of adverse immune events and have been successfully implemented with our pharmaceutical partners. Alcyomics® has used its extensive knowledge of 3D culture systems to develop 3D models of both Osteoarthritis and Innervated skin as tools for drug discovery applications.
Draper uses microfluidics, cell and molecular biology, and complex instrumentation to design biological systems and develop prototype technologies compatible with a wide range of biological materials,ranging in size scale from the molecular level up to the cell and tissue level. Drawing on its knowledge of immunology and microfluidics, Draper designs and develops manufacturing tools for cellular therapies. Draper engineers new capabilities by seamlessly integrating novel biological systems with custom hardware for a wide range of applications, including controlled DNA synthesis, cellular therapy manufacturing, detection, diagnostics, high-throughput R&D and therapeutic screening
Curi Bio provides a seamless, bioengineered integration of human stem cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues—with a focus on cardiac, skeletal muscle, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new therapeutics. Curi seeks to de-risk and expedite the development of new drugs by decreasing the industry’s dependence on animal models, which often fail to translate to humans. By providing researchers human-relevant preclinical data at the earliest stages of the development pipeline, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
CELLINK is the leading bio-convergence company and a global provider of technologies, products and services to create, understand and master biology. With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications.
CELLINK is creating the future of medicine.
CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.
CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. The company’s plant-based technology allows mass production of Type I recombinant human collagen (rhCollagen), which is identical to the collagen produced by the human body, making it the ideal building block for regenerative medicine. CollPlant now offers Collink.3DTM, human collagen bioink platform, for biofabrication of scaffolds, tissues and organs for 3D modeling and therapeutic applications.
Inventia Life Science is an Australian biotechnology company that's developed a revolutionary 3D cell culture technology to enhance the way preclinical biomedical research and drug discovery is conducted. Inventia’s flagship product, RASTRUM™ platform is a game changer in creating 3D cell cultures through a combination of the drop-on-demand bioprinting technology and the proprietary hydrogel matrix, which enables a highly reproducible and biologically tunable environment for the cells to thrive in, mimicking human tissue and diseases.
Crown Bioscience is a cutting-edge translational technology company providing drug discovery and preclinical development services in the areas of oncology, immunology,
inflammation, cardiovascular, and metabolic disease. We bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates. Our premier
translational platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs.
Glauconix Biosciences novel 3D human tissue models and proprietary physiologic testing platforms have been used from discovery through clinical efforts. We have validated models for glaucoma (human trabecular meshwork, Schlemm’s canal and trabecular outflow tract) and a recently released 3D retinal vasculature model for DR/DME that recapitulates the retina microvasculature that incorporates human retinal pericyte cells.